Breast cancer-related Lymphedema, BCRL
Conditions
Interventions
Treatment group:Transcutaneous Electrical Acupoint Stimulation treatment
Control group:sham Transcutaneous Electrical Acupoint Stimulation treatment
Sponsors
Yunnan Provincial Hospital of TCM
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Patients who meet the above diagnostic criteria and whose clinical stage of breast cancer belongs to stage II or III; (2) Have undergone preoperative puncture, confirmed the diagnosis of invasive breast cancer and axillary lymph node metastasis, and are proposed to undergo axillary lymph node dissection; (3) No upper extremity lymphedema before surgery; (4) The age of onset is 18-75 years old; (5) Survival period of =3 years as clinically predicted by the surgeon; (6) Clear consciousness, no mental illness, no heart, liver, cerebrovascular, renal and other systemic diseases, independent daily life, able to cooperate with the completion of all interventions; (7) They should be completely voluntary and sign an informed consent form, and be willing to cooperate in receiving follow-up visits during the study period.
Exclusion criteria
Exclusion criteria: (1) Do not meet the above inclusion criteria; (2) Patients who are currently on medications or other treatment regimens that conflict with this case; (3) Patients with mental abnormalities, combined with severe cardiovascular, cerebrovascular, hepatic and renal disorders; (4) Those who have other diseases that are not suitable for the implementation of the program, such as skin diseases, coagulation disorders or infectious diseases. (5) Pregnant and lactating women; (6) Upper limb disability with cardiogenic, nephrogenic or malnutrition-induced edema. (7) Presence of venous thrombosis in the affected limb. (8) Patients who have a history of surgery or injury to the affected upper limb before breast cancer surgery;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| visual analogue scale(VAS);Symptoms related to lymphedema;Comparison of Upper Limb Circumference Changes and Staging/Severity of Edema; | — |
Secondary
| Measure | Time frame |
|---|---|
| Lymphatic System Imaging;Security Assessment;Serum Tumor Necrosis Factor-a (TNF-a), High-Sensitivity C-Reactive Protein (hs-CRP), Procalcitonin (PCT); | — |
Countries
China
Contacts
Public ContactZhao Rong
Yunnan Provincial Hospital of TCM/ Yunnan University of Chinese Medicine
Outcome results
None listed